AVIEW LCS vs SENSICARDIAC

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft Co.

SENSICARDIAC

by Diacoustic Medical Devices (Pty) Ltd.

AI Verdict

AVIEW LCS is designed for comprehensive cardiopulmonary assessment from CT scans, including coronary artery calcification and lung nodule analysis. In contrast, SENSICARDIAC specializes in AI-powered heart murmur detection and classification using electronic stethoscope data. While both contribute to cardiac care, they utilize distinct data modalities and address different diagnostic needs.

Choose AVIEW LCS if…

Choose AVIEW LCS if your practice requires a comprehensive, AI-driven solution for analyzing low-dose CT scans to screen for lung cancer, assess COPD, and quantify coronary artery calcification simultaneously. This tool is ideal for radiologists and pulmonologists seeking automated nodule detection, Lung-RADS classification, and detailed cardiopulmonary reports to streamline diagnostic workflows and enhance accuracy in a single scan.

View AVIEW LCS →

Choose SENSICARDIAC if…

Choose SENSICARDIAC if you need an AI-powered, cloud-based service to accurately detect and classify heart murmurs using electronic stethoscopes, particularly in primary care, pediatrics, or telehealth settings. This solution is best suited for physicians aiming to quickly differentiate between pathological and physiological murmurs, reduce unnecessary specialist referrals, and provide advanced remote cardiac care with real-time auscultation analysis.

View SENSICARDIAC →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	SENSICARDIAC
Pricing	Contact for pricing	Unknown
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	SensiCardiac is a software package running on a Windows PC that interfaces with compatible electronic stethoscopes. SensiCardiac Mobi runs on a mobile device (iPhone 4S or later) and interfaces with a hosted Linux server environment. The related Telesensi platform operates entirely in the browser.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS offers extensive integration with existing radiology workflows, including PACS/RIS, DICOM output, and automated report generation, significantly streamlining diagnostic processes and reducing radiologist workload and interpretation time. It also provides flexible deployment options and an intuitive 3D viewer for both professionals and patients. While SENSICARDIAC offers a guided auscultation process and user-friendly interface, AVIEW LCS's broader and deeper integration into complex radiology environments provides a more impactful usability enhancement for its target users.

Clinical Value

AVIEW LCS

Both tools are FDA-cleared and provide significant clinical benefits. AVIEW LCS offers a comprehensive, integrated solution for detecting and analyzing lung nodules, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and efficiency, and is adopted in national screening programs. SENSICARDIAC accurately detects and classifies heart murmurs to aid diagnosis and reduce unnecessary referrals, with reported high accuracy. However, AVIEW LCS's multi-disease assessment from a single scan and its proven impact on radiologist efficiency across large-scale deployments demonstrate a broader clinical impact.

Pricing & Value

SENSICARDIAC

Neither tool provides fully transparent pricing in their specifications. However, SENSICARDIAC, through its associated Telesensi platform, offers an indicative subscription model with a per-user per-month price range, providing some level of transparency for potential buyers. AVIEW LCS's pricing remains entirely undisclosed, requiring direct contact for information. Therefore, SENSICARDIAC offers slightly more insight into its pricing structure.

Enterprise Readiness

AVIEW LCS

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs. AVIEW LCS stands out with its highly flexible deployment options (cloud, hybrid, local, virtualized) and deep integration capabilities with PACS/RIS and other third-party platforms, which are critical for large enterprise healthcare systems. Its widespread adoption in major government-led lung cancer screening programs across multiple countries further validates its scalability and proven readiness for enterprise-level deployment. SENSICARDIAC, while offering cloud and desktop deployment and white-labeling, has a more focused integration scope.

Innovation

AVIEW LCS

Both tools demonstrate innovation in their respective fields. AVIEW LCS represents a significant innovation by integrating fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, creating an 'integrated diagnostic ecosystem' and streamlining multi-disease screening. SENSICARDIAC innovates with its AI-powered, real-time heart murmur detection integrated with electronic stethoscopes for remote care, with future plans for 'headless murmur detection' and 'out-of-band audio' for telehealth. AVIEW LCS's comprehensive, multi-pathology assessment from a single imaging modality represents a broader and more complex innovation in diagnostic imaging.

Support & Docs

SENSICARDIAC

While neither JSON provides explicit details, web searches indicate SENSICARDIAC (via Telesensi) offers structured support including new user training, demo sessions, and readily available user manuals, setup guides, and troubleshooting information. AVIEW LCS mentions contacting their website or a specific email for information and refers to user manuals. SENSICARDIAC's explicit mention of comprehensive training and a broader range of documented support resources suggests a more transparent and accessible support structure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	SENSICARDIAC
Name	AVIEW LCS	SENSICARDIAC
Company	Coreline Soft Co.	DIACOUSTIC MEDICAL (PTY)
Tagline	AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment	Advanced remote cardiac care solution with LIVE diagnostic quality stethoscope streaming and AI heart murmur screening.
Primary Function	AI-powered solution for the detection and analysis of lung nodules, COPD, and coronary artery calcification from a single low-dose CT scan.	AI-powered, cloud-based heart murmur detection service that integrates with electronic stethoscopes to classify murmurs as pathological or physiological.
Key Features (Examples)	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Coronary Artery Calcification (CAC) scoring.	AI-powered heart murmur detection, Integration with electronic stethoscopes, Classification of murmurs (pathological/physiological).
Specialties	Cardiology, Oncology, Pulmonology, Radiology	Cardiology, Internal Medicine, Pediatrics

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and SENSICARDIAC.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for different specialties, and what specific clinical problems do they address?

AVIEW LCS is designed to integrate into radiology workflows, providing AI-powered analysis of CT scans for lung nodules, COPD, and coronary artery calcification, aiding radiologists, pulmonologists, and oncologists in diagnosis and follow-up. SENSICARDIAC integrates with electronic stethoscopes at the point of care to classify heart murmurs as pathological or physiological, assisting cardiologists, internists, and pediatricians in reducing unnecessary referrals and improving diagnostic accuracy during physical exams.

What is the extent of EHR integration for each tool, beyond basic report generation, to ensure seamless data flow and accessibility?

AVIEW LCS offers robust integration with PACS/RIS and other third-party platforms, supporting DICOM output, worklist integration, and pre-populated reports, which facilitates a 'zero-click' AI workflow within existing imaging systems. SENSICARDIAC generates detailed cardiac reports in downloadable PDF format, which can be incorporated into an EHR, but the description does not explicitly detail direct, real-time data exchange capabilities with EHR systems beyond report output.

What is the basis for the accuracy and sensitivity claims of each tool in their respective diagnostic areas?

AVIEW LCS has demonstrated high detection sensitivity (u2265 83%) and precision (u2264 10% volumetric error for nodules > 6 mm) for lung nodule detection, and has shown a 100% detection rate for reference positive cancers in 3-month follow-up scans. SENSICARDIAC classifies heart murmurs by analyzing recordings against a large, validated database of pathological heart murmurs, with reported accuracy above 95 percent, aiming to reduce unnecessary referrals.

What is the typical learning curve for physicians and their staff to effectively utilize each tool, and how quickly can a practice expect to see value?

AVIEW LCS, with its automated analysis and comprehensive report generation, aims to reduce reading time by up to 60% and workload by 86.7%, suggesting that while initial familiarization with its output and integration into radiology workflows is needed, it offers significant time savings. SENSICARDIAC's guided auscultation process and real-time classification are designed for ease of use, and studies on AI-guided cardiac imaging suggest novices can achieve diagnostic-quality results after short training periods, potentially offering rapid time-to-value.

What audit-trail capabilities does each tool offer to track AI-assisted diagnoses, physician overrides, and changes for documentation and quality assurance?

AVIEW LCS provides automated comparison of nodules in follow-up CT scans and generates comprehensive, automated reports, which inherently creates a record of the AI's analysis and any subsequent physician input for longitudinal tracking. SENSICARDIAC generates detailed, downloadable cardiac reports that document the AI's classification and associated data, serving as an auditable record of each patient encounter.

What are the key considerations for deploying each tool across multiple clinical sites or a large healthcare system?

AVIEW LCS offers flexible deployment options including cloud, hybrid, and local solutions, and has been successfully rolled out across networks of radiology centers in a short timeframe, supporting large-scale, multi-center screening operations. SENSICARDIAC's cloud-based service model inherently supports multi-site deployment, requiring electronic stethoscopes and internet access at each location, with user management and billing systems designed for multiple facilities.